7-benzyl-2-chloro-1-methyl-1,7-dihydro-6H-purin-6-one | 140379-24-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 7-benzyl-2-chloro-1-methyl-1,7-dihydro-6H-purin-6-one
• 英文别名: 2-chloro-1-methyl-7-(phenylmethyl)purin-6-one；7-benzyl-2-chloro-1-methylpurin-6-one
• CAS: 140379-24-4
• 化学式: C₁₃H₁₁ClN₄O
• 分子量: 274.71
• InChiKey: FHJHVHCVYRREAY-UHFFFAOYSA-N

物化性质

• 沸点：
  496.5±37.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  50.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-benzyl-2-chloro-1-methyl-1,7-dihydro-6H-purin-6-one 在 sodium tetrahydroborate 、 正丁基锂 、 氯化亚砜 、 sodium methylate 、 二异丙胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 9.5h， 生成 (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-2-(methoxymethyl)-5-methyl-3-(phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one
  参考文献：
  名称：

  Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity

  摘要：

  Tetracyclic guanines have been shown to be potent and selective inhibitors of the cGMP-hydrolyzing enzymes PDE1 and PDE5. In general, these compounds are inactive or only weakly active as inhibitors of PDE3, which is a major isozyme involved in cAMP hydrolysis. Structure-activity relationships are developed at N-1, C-2, N-3, and N-5 on the core nucleus. Compound 31, with an IC50 of 70 pM, is the most potent inhibitor of PDE1, while 50, with an IC50 of 4 nM, is the most potent inhibitor of PDE5. Compounds 20, 22, 30, and 50 are potent dual inhibitors with IC50 values below 30 nM for both PDE1 and PDE5. Compounds 12, 20, and 28 reduced blood pressure by more than 45 mmHg when administered orally at 10 mg/kg to the spontaneously hypertensive rat (SHR).

  DOI：

  10.1021/jm9608467
• 作为产物：
  描述：

  6-amino-5-(benzylamino)-3-methylpyrimidine-2,4(1H,3H)-dione 在 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 7-benzyl-2-chloro-1-methyl-1,7-dihydro-6H-purin-6-one
  参考文献：
  名称：

  Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity

  摘要：

  Tetracyclic guanines have been shown to be potent and selective inhibitors of the cGMP-hydrolyzing enzymes PDE1 and PDE5. In general, these compounds are inactive or only weakly active as inhibitors of PDE3, which is a major isozyme involved in cAMP hydrolysis. Structure-activity relationships are developed at N-1, C-2, N-3, and N-5 on the core nucleus. Compound 31, with an IC50 of 70 pM, is the most potent inhibitor of PDE1, while 50, with an IC50 of 4 nM, is the most potent inhibitor of PDE5. Compounds 20, 22, 30, and 50 are potent dual inhibitors with IC50 values below 30 nM for both PDE1 and PDE5. Compounds 12, 20, and 28 reduced blood pressure by more than 45 mmHg when administered orally at 10 mg/kg to the spontaneously hypertensive rat (SHR).

  DOI：

  10.1021/jm9608467

文献信息

• Polycyclic guanine derivatives
  申请人：Schering Corporation

  公开号：US05393755A1

  公开（公告）日：1995-02-28

  Novel polycylic guanine derivatives of the formula: ##STR1## wherein J is oxygen or sulfur, R.sup.1 is hydrogen, alkyl or alkyl substituted with aryl or hydroxy; R.sup.2 is hydrogen, aryl, heteroaryl, cycloalkyl, alkyl or alkyl substituted with aryl, heteroaryl, hydroxy, alkoxy, amino, monoalkyl amino or dialkylamino, or --(CH.sub.2).sub.m TCOR.sup.20 wherein m is an integer from 1 to 6, T is oxygen or --NH-- and R.sup.20 is hydrogen, aryl, heteroaryl, alkyl or alkyl substituted with aryl or heteroaryl; R.sup.3 is hydrogen, halo, trifluoromethyl, alkoxy, alkylthio, alkyl, cycloalkyl, aryl, aminosulfonyl, amino, monoalkylamino, dialkylamino, hydroxyalkylamino, aminoalkylamino, carboxy, alkoxycarbonyl or aminocarbonyl or alkyl substituted with awl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino; R.sup.a, R.sup.b, R.sup.c, and R.sup.d are defined in the specification; and n is zero or one. The compounds of formulas (I) and (I') are useful as antihypertensive, muscle relaxant and bronchodilating agents.

  新颖的多环鸟嘌呤衍生物的化学式为：##STR1## 其中J为氧或硫，R.sup.1为氢，烷基或烷基取代芳基或羟基；R.sup.2为氢，芳基，杂环芳基，环烷基，烷基或烷基取代芳基，杂环芳基，羟基，烷氧基，氨基，单烷基氨基或二烷基氨基，或--(CH.sub.2).sub.m TCOR.sup.20，其中m为1到6的整数，T为氧或--NH--，R.sup.20为氢，芳基，杂环芳基，烷基或烷基取代芳基或杂环芳基；R.sup.3为氢，卤素，三氟甲基，烷氧基，硫烷基，烷基，环烷基，芳基，氨基磺酰基，氨基，单烷基氨基，二烷基氨基，羟基烷基氨基，氨基烷基氨基，羧基，烷氧羰基或氨基羰基或烷基取代芳基，羟基，烷氧基，氨基，单烷基氨基或二烷基氨基；R.sup.a，R.sup.b，R.sup.c和R.sup.d在规范中有定义；n为零或一。化合物的化学式(I)和(I')可用作降压、肌肉松弛和扩张支气管剂。
• [EN] IMIDAZO [2,1-B] PURINE DERIVATIVES AS TRPA1 MODULATORS<br/>[FR] DÉRIVÉS D'IMIDAZO[2,1-B]PURINE EN TANT QUE MODULATEURS DE TRPA1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2009144548A1

  公开（公告）日：2009-12-03

  The present invention provides TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPAl (Transient Receptor Potential subfamily A, member 1) modulators. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPAl.

  本发明提供了TRPA（瞬时受体电位亚家族A）调节剂。具体而言，本文描述的化合物可用于治疗或预防由TRPAl（瞬时受体电位亚家族A，成员1）调节剂调节的疾病、症状和/或疾病。此外，本文还提供了制备本文描述的化合物的方法、用于合成的中间体、药物组合物以及用于治疗或预防由TRPAl调节的疾病、症状和/或疾病的方法。
• POLYCYCLIC GUANINE DERIVATIVES
  申请人：SCHERING CORPORATION

  公开号：EP0538332A1

  公开（公告）日：1993-04-28
• US5393755A
  申请人：——

  公开号：US5393755A

  公开（公告）日：1995-02-28
• US5939419A
  申请人：——

  公开号：US5939419A

  公开（公告）日：1999-08-17